Rhythm Pharmaceuticals Stock Performance
| RYTM Stock | USD 53.72 1.68 3.23% |
The company holds a Beta of 0.71, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Rhythm Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Rhythm Pharmaceuticals is expected to be smaller as well. At this point, Rhythm Pharmaceuticals has a negative expected return of -0.0526%. Please make sure to check Rhythm Pharmaceuticals' total risk alpha, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Rhythm Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Rhythm Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Rhythm Pharmaceuticals is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 3.23 | Five Day Return (1.56) | Year To Date Return (10.57) | Ten Year Return 79.07 | All Time Return 79.07 |
1 | Disposition of 30771 shares by Pamela Cramer of Rhythm Pharmaceuticals at 19.02 subject to Rule 16b-3 | 01/13/2025 |
2 | Wall Street Analysts Think Rhythm Pharmaceuticals Could Surge 26.36 percent Read This Before Placing a Bet | 01/28/2025 |
3 | Disposition of 2650 shares by Pamela Cramer of Rhythm Pharmaceuticals subject to Rule 16b-3 | 01/31/2025 |
4 | Disposition of 902 shares by Pamela Cramer of Rhythm Pharmaceuticals at 59.43 subject to Rule 16b-3 | 02/04/2025 |
5 | Disposition of 4062 shares by Smith Hunter C of Rhythm Pharmaceuticals subject to Rule 16b-3 | 02/07/2025 |
6 | Disposition of 2295 shares by Jennifer Lee of Rhythm Pharmaceuticals at 59.3408 subject to Rule 16b-3 | 02/10/2025 |
7 | Disposition of 2343 shares by Smith Hunter C of Rhythm Pharmaceuticals subject to Rule 16b-3 | 02/11/2025 |
8 | Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on ... | 02/13/2025 |
9 | Disposition of 3300 shares by Pamela Cramer of Rhythm Pharmaceuticals subject to Rule 16b-3 | 02/14/2025 |
10 | Disposition of 982 shares by Pamela Cramer of Rhythm Pharmaceuticals at 57.22 subject to Rule 16b-3 | 02/19/2025 |
11 | Rhythm Pharmaceuticals Inc Reports Strong Q4 2024 Financial Results and Strategic ... | 02/26/2025 |
12 | Rhythm Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript | 02/27/2025 |
13 | Rhythm Pharmaceuticals Full Year 2024 Earnings Revenues Beat Expectations, EPS In Line | 03/03/2025 |
14 | HC Wainwright Issues Positive Estimate for RYTM Earnings | 03/06/2025 |
15 | SBI Securities Co. Ltd. Invests 37,000 in Rhythm Pharmaceuticals, Inc. - Defense World | 03/12/2025 |
16 | Disposition of 75000 shares by Yann Mazabraud of Rhythm Pharmaceuticals at 22.28 subject to Rule 16b-3 | 03/14/2025 |
17 | Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan | 03/19/2025 |
18 | Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE in China with Termination of Agreement with RareStone Ltd. | 03/20/2025 |
19 | Disposition of 344 shares by Christopher German of Rhythm Pharmaceuticals at 54.23 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 60.4 M |
Rhythm |
Rhythm Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,654 in Rhythm Pharmaceuticals on December 25, 2024 and sell it today you would lose (282.00) from holding Rhythm Pharmaceuticals or give up 4.99% of portfolio value over 90 days. Rhythm Pharmaceuticals is currently does not generate positive expected returns and assumes 2.6377% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Rhythm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rhythm Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rhythm Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rhythm Pharmaceuticals, and traders can use it to determine the average amount a Rhythm Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.02
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RYTM |
Estimated Market Risk
| 2.64 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rhythm Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rhythm Pharmaceuticals by adding Rhythm Pharmaceuticals to a well-diversified portfolio.
Rhythm Pharmaceuticals Fundamentals Growth
Rhythm Stock prices reflect investors' perceptions of the future prospects and financial health of Rhythm Pharmaceuticals, and Rhythm Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rhythm Stock performance.
| Return On Equity | -1.56 | ||||
| Return On Asset | -0.46 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | (0.99) % | ||||
| Current Valuation | 3.12 B | ||||
| Shares Outstanding | 63.22 M | ||||
| Price To Book | 151.42 X | ||||
| Price To Sales | 25.28 X | ||||
| Revenue | 130.13 M | ||||
| Gross Profit | 116.76 M | ||||
| EBITDA | (238.09 M) | ||||
| Net Income | (260.6 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 3.94 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (113.88 M) | ||||
| Earnings Per Share | (4.34) X | ||||
| Market Capitalization | 3.29 B | ||||
| Total Asset | 392.27 M | ||||
| Retained Earnings | (1.16 B) | ||||
| Working Capital | 258.68 M | ||||
About Rhythm Pharmaceuticals Performance
By examining Rhythm Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Rhythm Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rhythm Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 511.70 | 283.38 | |
| Return On Tangible Assets | (0.67) | (0.71) | |
| Return On Capital Employed | (0.96) | (0.91) | |
| Return On Assets | (0.66) | (0.70) | |
| Return On Equity | (11.99) | (11.39) |
Things to note about Rhythm Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rhythm Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rhythm Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rhythm Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 130.13 M. Net Loss for the year was (260.6 M) with profit before overhead, payroll, taxes, and interest of 116.76 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (113.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Rhythm Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Disposition of 344 shares by Christopher German of Rhythm Pharmaceuticals at 54.23 subject to Rule 16b-3 |
- Analyzing Rhythm Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rhythm Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rhythm Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rhythm Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rhythm Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rhythm Pharmaceuticals' stock. These opinions can provide insight into Rhythm Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.34) | Revenue Per Share | Quarterly Revenue Growth 0.726 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.